ArticleCureus2026
Malignant Proliferating Trichilemmal Tumor of the Scalp Treated With Excision and Adjuvant Radiotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proliferating trichilemmal cysts are common benign lesions, but their malignant counterpart, malignant proliferating trichilemmal tumor (MPTT), is an extremely rare adnexal malignancy that predominantly arises on the scalp. Due to clinical and histological overlap, it is frequently misdiagnosed as squamous cell carcinoma. We report the case of a 70-year-old woman who presented with a progressively enlarging, painless, and bleeding midline scalp mass evolving over one year. A craniofacial CT scan (SOMATOM, Siemens Healthineers, Erlangen, Germany) revealed a well-defined, heterogeneous soft-tissue lesion measuring 75 × 55 mm without underlying bone lysis. Systemic staging showed no distant metastases. An initial incisional biopsy suggested squamous cell carcinoma. The patient underwent wide surgical excision with 1-cm safety margins and deep periosteal bed re-excision. Tension-free primary closure was achieved following extensive scalp undermining and galeal scoring. Definitive histopathological and immunohistochemical examination confirmed MPTT with clear margins. Due to the tumor size and high mitotic rate, the patient received adjuvant hypofractionated Volumetric Modulated Arc Therapy (VMAT; Elekta AB, Stockholm, Sweden), delivering 45 Gy in 10 fractions, resulting in a favorable clinical outcome without recurrence at six months of follow-up. While short-term results demonstrate a favorable outcome, extended surveillance is mandatory due to the potential for late recurrence or metastasis. This case highlights the critical importance of accurate clinical, radiological, and especially histopathological diagnosis using immunohistochemistry to differentiate MPTT from squamous cell carcinoma, ensuring optimal surgical margins and appropriate adjuvant management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.